Date: 2011-09-06
Type of information: Fundraising
Company: Amakem (Belgium)
Investors: Forbion Capital Partners (The Netherlands) - Crédit Agricole Private Equity (France) - Vesalius BioCapital (Luxembourg) - LRM (Belgium) - PMV (Belgium) - Life Sciences Research Partners (Belgium)
Amount: € 18 million
Funding type: Series A financing round
Planned used: Amakem has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept. AMA0076 is a novel, highly potent Rho Kinase (ROCK) inhibitor for the treatment of glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness. AMA0076 has been proven in preclinical models to be highly effective in reducing intraocular pressure (IOP), a major factor in glaucoma, and to avoid important side effects such as hyperemia. Hyperemia, also known as ‘red eye’, results from excess blood flow in vessels in the white of the eye and is a distressing and dose limiting side effect for patients.
Others:
Therapeutic area: Ophtalmological diseases
